Stockreport
The Trump administration has halted funds for global HIV/AIDS programs. No one knows how big the impact is [CNN]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
The full extent of the budget cuts related to US-funded HIV/AIDS relief work is highly unclear, and Congress is still battling the White House's proposed budget clawbacks and withholding of billions of dollars in funding. PEPFAR, formally called the US President's Emergency Plan for AIDS Relief, is credited with saving more than 26 million lives over the past two decades and preventing millions of HIV infections, particularly in Africa. Last year alone, government figures show that PEPFAR provided 20.6 million people with life-saving HIV medicines, called antiretroviral therapy. It also supported more than 342,000 health workers to deliver HIV treatments, prevention care and support services, bolstering healthcare systems in more than 50 countries Funding for the landmark program – established in 2003 by the Bush administration – was primarily implemented by USAID, which US President Donald Trump dismantled earlier this year after a freeze on foreign aid. The US State Departmen
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise [Yahoo! Finance][Yahoo! Finance]
- Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences to Present at Upcoming Investor Conference[Business Wire]
- Biopharma climbs higher as 9 drugmakers ink ‘pandering' drug price deals with Trump [Yahoo! Finance][Yahoo! Finance]
- 3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- GILD's page on the SEC website
- More